Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.94 |
| ▸ | MMP3 | P08254 | 14/20 | 0.94 |
| ▸ | MMP1 | P03956 | 12/20 | 0.94 |
| ▸ | MMP2 | P08253 | 12/20 | 0.94 |
| ▸ | MMP9 | P14780 | 11/20 | 0.94 |
| ▸ | MMP8 | P22894 | 11/20 | 0.94 |
| ▸ | MMP7 | P09237 | 10/20 | 0.94 |
| ▸ | STS | P08842 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350049 | 1.00 | MMP13 (0.94) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7249879 | 0.97 | MMP13 (1.00) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7255903 | 0.92 | MMP13 (0.80) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7256569 | 0.90 | MMP13 (0.78) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL6290994 | 0.89 | MMP13 (0.86) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7254724 | 0.88 | MMP13 (0.81) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7250944 | 0.88 | MMP13 (1.00) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7358009 | 0.86 | MMP13 (0.72) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL7350181 | 0.86 | MMP13 (0.72) | MMP13MMP3MMP1MMP2MMP9 | |
| SCHEMBL3255049 | 0.86 | MMP13 (0.84) | MMP13MMP3MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| US-5817822-A | ANTITUOR, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | NOVARTIS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |